Jan Sloves: Understanding Iliofemoral DVT – What You Can’t Afford to Miss
Jan Sloves, President and Consultant at Vascular Imaging Professionals LLC, shared on LinkedIn:
”Understanding Iliofemoral DVT: What You Can’t Afford to Miss
Here’s an excellent real-world example — a symptomatic 57-year-old female being treated for breast CA who presented to the ER with an iliofemoral DVT.
On duplex, you can clearly see the thrombus wrapping around the femoral head and extending up toward the confluence.
What’s really important to remember is that in about 80% of patients with iliofemoral DVT, there’s an underlying proximal stenosis — often masked by overlying arterial structures.
When you take a closer look at the posterior wall, you can actually appreciate the intraluminal changes that have developed over time.
These subtle findings tell a bigger story about chronicity and hemodynamic impact — and they’re key to guiding the right treatment decisions.
If you’re passionate about understanding these nuances and improving your scan interpretation, join our growing community at Ultrasound Unlocked — a place where sonographers and physicians learn, share, and refine their craft together.”

Stay updated with Hemostasis Today.
-
Mar 16, 2026, 15:18Kalpana Gupta Shekhawat: A Practical Clinical Approach to Iron Regulation
-
Mar 16, 2026, 15:08Mohamed Sikkander Abdul Razak: Warning Signs of Vitamin Deficiencies
-
Mar 16, 2026, 15:05Kate Thomas: Plasma Donations Drive New Era of Life-Saving Medicines in the UK
-
Mar 16, 2026, 14:52Gianluca Franceschini: The Difference in Breast Cancer is Made by the Team
-
Mar 16, 2026, 14:51Heghine Khachatryan: Hematologic Causes of Cryptogenic Stroke
-
Mar 16, 2026, 14:35Simon Senanu: Understanding the Extrinsic Coagulation Pathway
-
Mar 16, 2026, 14:27Mahesan Subramaniam: Why Messy Spaces Impact Women’s Stress Levels More Than Men’s
-
Mar 16, 2026, 14:21Marlies Alvarenga: Balancing the Scales in Women’s Cardiovascular Health
-
Mar 16, 2026, 13:32Filippo Cademartiri: Inflammation vs Cholesterol as Driver of Residual ASCVD Risk